DEPRESSION AND ANXIETY 27 : 390–403 (2010
Hесмотря на многочисленные международные договоры и обязательства по защите прав мигрантов в области здравоохранения, эта ключевая затронутая группа населения п... прежнему испытывает серьезные затруднения в доступе к лечению от туберкулеза. Миграция вызвана рядом сложных экономических, социальных, политических и экологических факторов и является определяющим элементом плохого здоровья, а результаты лечения мигрантов находятся под воздействием различных измерений миграционного процесса.
Accessed on 2019
more
Contributions in International Seminars 1988 -2008
Intercultural Pastoral Care and Counselling, no. 20
Global and Regional Data 1 December 2021; The 90–90–90 targets were missed, but not by much. At the end of 2020, 84% of people living with HIV knew their HIV status, 87% of people living with HIV who knew their HIV status were accessing antiretroviral therapy, and 90% of people on treatment were... virally suppressed.
more
This resource aims to provide relevant and practical guidance to DRR practitioners (policy and programme colleagues), on how to ensure inclusion - particularly of vulnerable groups - in Community-Based DRR (CBDRR) initiatives in Myanmar. It comprises an overall Framework for inclusive CBDRR and a nu...mber of tools/resources including: 1) a checklist for inclusion in the 7 steps of the CBDRR process, 2) a guideline for documenting inclusion, 3) a template for assessing inclusion and 4) a compendium of tools and guidelines relevant to inclusive CBDRR.
The Inclusive Framework and Toolkit for Community-Based DRR in Myanmar is a resource produced by the Myanmar Consortium for Community Resilience (MCCR), a consortium led by ActionAid, with ACF, HelpAge, Oxfam, Plan and UN-Habitat.
more
2018 Progress Report
PEPFAR Strategy for Accelerating HIV/AIDS Epidemic Control (2017-2020)
The COVID-19 pandemic presents a rare and immediate opportunity for a norm shift towards localisation in the humanitarian architecture. Whils tinternational humanitarian actors are facing constraints in funding and restrictions on movement and travel, national and local level ...humanitarian actors are on the ground to respond. A timely investment in localcapacities and capabilities creates a strong platform for effective, efficientand sustained response and recovery from the impact of the COVID-19 pandemic in the days, months and years ahead.
more
Education for respect and understanding – inclusion and equity
This FY 2017 Malaria Operational Plan presents a detailed implementation plan for Senegal, based on the strategies of PMI and the National Malaria Control Program (NMCP) strategy. It was developed in consultation with the NMCP and with the participation of national and international partners involve...d in malaria prevention and control in the country. The activities that PMI is proposing to support fit in well with the new National Malaria Control strategy and plan (2016-2020) and build on investments made by PMI and other partners to improve and expand malaria-related services, including the Global Fund to Fight AIDS, Tuberculosis, and Malaria (Global Fund) malaria grants. This document briefly reviews the current status of malaria control policies and interventions in Senegal, describes progress to date, identifies challenges and unmet needs to achieving the targets of the NMCP and PMI, and provides a description of activities that are planned with FY 2017 funding.
more
PLOS ONE | www.plosone.org
September 2014 | Volume 9 | Issue 9 | e103657
Despite high regional demand for vaccines valued at over US$ 1 billion annually, Africa’s vaccine industry provides only 0.1% of global supply. Vaccine inequity and hoarding at the start of the pandemic, which resulted in delays in obtaining COVID-19 doses, stimulated new resolve to address future... supply security. In 2021, the AU set a target to produce and supply more than 60% of the vaccine doses on the continent by 2040.
In the last 18 months alone, more than 30 new African manufacturing projects have been announced and estimates indicate that the African vaccine market across all existing and projected novel products could range between US$ 2.8 billion and US$ 5.6 billion by 2040*, demonstrating the potential for a thriving regional industry to emerge.
more